Andreas Kjær

Andreas Kjær

Professor


  1. 2011
  2. Udgivet

    Temozolomide as 2nd-3rd Line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas

    Olsen, I. H., Federspiel, B., Kjær, Andreas, Hansen, C. P., Knigge, Ulrich & Langer, Seppo W., 2011, s. 38-38. 1 s.

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningfagfællebedømt

ID: 13402